Local Non-salvage Radiotherapy for Synchronous Oligometastatic Non-small-cell Lung Cancer :A Multicenter,Randomized,Controlled,Phase 2 Study.

NCT03119519 Phase 2 UNKNOWN

Aggressive therapy may improve survival in synchronous oligometastatic NSCLC and the goal of this clinical trial is to assess the efficacy and safety of local definitive radiotherapy in this subset of patients.

Details

Lead sponsor	Southern Medical University, China
Phase	Phase 2
Status	UNKNOWN
Enrolment	148
Start date	2017-12-11
Completion	2021-09

Conditions

• Stage IV Non-small Cell Lung Cancer

Interventions

• Local Definitive Radiotherapy
• No Local Definitive Radiotherapy

Primary outcomes

• Progression-free Survival (PFS) — 5 years
  Refers to the time from randomization to disease progression or death.

Countries

China